https://www.pharmacompass.com/fda-orange-book-exclusivity always 0.8 https://www.pharmacompass.com/fda-orange-book-exclusivity/fidaxomicin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/givinostat-hcl yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/linagliptin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/selumetinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/chenodeoxycholic-acid yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/odevixibat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tofacitinib-citrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/apixaban yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tasimelteon yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sparsentan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/edoxaban-tosylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/binimetinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/palovarotene yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/relugolix yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bempedoic-acid yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/perfluorohexyloctane yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/glycerol-phenylbutyrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/imipenem yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bosentan-hydrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tafamidis yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/treprostinil-diolamine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lenvatinib-mesylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/rezafungin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/mavorixafor yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/acoltremon yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/trofinetide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ponesimod yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tedizolid yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pazopanib-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pitolisant-hydrochloride-11551689 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/carfilzomib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/apremilast yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/delafloxacin-meglumine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/crizotinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/samidorphan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/trametinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/rilpivirine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fezolinetant yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/elamipretide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/mavacamten yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vorasidenib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/belzutifan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/avapritinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/remibrutinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ritlecitinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/brensocatib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/risdiplam yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/olutasidenib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vosoritide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fitusiran yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/empagliflozin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/belumosudil yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/indocyanine-green yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/brexpiprazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bosutinib-monohydrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/setmelanotide-acetate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/acetylcysteine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lazertinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/remdesivir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sebetralstat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/carglumic-acid yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bictegravir-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/capmatinib-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lutetium-177-vipivotide-tetraxetan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/aminolevulinic-acid-hcl yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/trilaciclib-dihydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/baloxavir-marboxil yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/inavolisib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/copper-cu-64-dotatate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/danicopan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dasiglucagon yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pralsetinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pirtobrutinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/levonorgestrel yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/magnesium-oxybate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cefiderocol-sulfate-tosylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/revumenib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/zilucoplan-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/paltusotine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/selpercatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/elexacaftor yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/mitapivat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pomalidomide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/deucravacitinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/acoramidis-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sepiapterin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fosdenopterin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pafolacianine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/zanubrutinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/repotrectinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sotorasib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/berotralstat-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ibrexafungerp-citrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ziftomenib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/adagrasib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/aficamten yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sunvozertinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/berdazimer-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/mobocertinib-succinate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/escitalopram-oxalate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/imlunestrant yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lonafarnib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pantoprazole-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ezetimibe yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/copper-histidine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lenacapavir-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dexmethylphenidate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/viltolarsen yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/deuruxolitinib-phosphate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sevabertinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/suzetrigine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/enzalutamide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/atrasentan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/resmetirom yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/macitentan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/nilotinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/zongertinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/elinzanetant yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/alogliptin-benzoate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lutetium-177 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/glucagon yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/liraglutide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/linaclotide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/afamelanotide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ivacaftor yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cobimetinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/gadopiclenol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/landiolol-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/nerandomilast yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lumacaftor yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/avutometinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fedratinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ferric-maltol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/aceclidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tofersen yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/eribulin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/esketamine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/deflazacort yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/paracetamol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/acyclovir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lenalidomide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lacosamide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cyclobenzaprine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vadadustat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tirbanibulin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sulopenem-etzadroxil yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/elacestrant yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cilastatin-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sodium-oxybate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sulbactam-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/riboflavin-5-phosphate-sodium-23666409 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/conjugated-estrogens yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/phenobarbital-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/potassium-oxybate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/rifamycin-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/olaparib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/copper yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/xenon yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/magnesium-sulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sodium-sulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sodium-thiosulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/potassium-sulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bupivacaine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bedaquiline yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/canagliflozin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ibrutinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ponatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sotagliflozin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/quizartinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/avibactam-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tafamidis-meglumine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/momelotinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/aprocitentan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/gepotidacin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cabozantinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ruxolitinib-phosphate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/entrectinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cobicistat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tovorafenib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tepotinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bexagliflozin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/capivasertib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cedazuridine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/estetrol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/clotrimazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/deferiprone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/diazepam yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/diazoxide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/daunorubicin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vamorolone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ivabradine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/omeprazole-magnesium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dasatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/articaine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/clobetasol-propionate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/carbidopa yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tobramycin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/hydroxyurea yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ibuprofen yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lidocaine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/iohexol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/iomeprol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/isopropyl-alcohol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/octreotide-acetate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/amikacin-sulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/letrozole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/edaravone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/metformin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/midazolam yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/meropenem yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/relebactam yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/leuprolide-acetate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/omidenepag-isopropyl yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lumateperone-tosylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/clindamycin-phosphate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/loteprednol-etabonate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fluticasone-propionate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vibegron yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fruquintinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vilanterol-trifenatate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dabrafenib-mesylate-44516822 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tacrolimus yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/crisaborole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/etrasimod-arginine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/roflumilast yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/letermovir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/decitabine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sofosbuvir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vonoprazan-fumarate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fenfluramine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pretomanid yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/olanzapine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cabotegravir-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pacritinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/nirogacestat-hydrobromide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/posaconazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/maribavir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/levoketoconazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/brincidofovir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/probenecid yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/avacopan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/venetoclax yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ferumoxytol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/triclabendazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/risperidone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/delgocitinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/encorafenib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tucatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/miglustat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/budesonide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/doxcercalciferol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/travoprost yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/crinecerfont yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/indigo-carmine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cyclosporine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sirolimus yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/topiramate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ozanimod yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/bimatoprost yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/iloprost yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/stiripentol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/infigratinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/alectinib-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/palbociclib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/zavegepant-hcl yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ephedrine-sulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/gallium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/nalmefene-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/naloxone-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vericiguat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/meloxicam yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/minocycline-hydrochloride-54685925 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/omadacycline yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cabotegravir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dolutegravir-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ceftazidime yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tiopronin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/gepirone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/alpelisib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vaborbactam yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/semaglutide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vortioxetine-hydrobromide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lemborexant yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/eravacycline-dihydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ensartinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/talazoparib-tosylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/eflornithine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lurbinectedin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ribociclib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dexamethasone-5743 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/mitomycin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/hydrocortisone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/estradiol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/thymidine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pibrentasvir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/norethisterone-acetate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/upadacitinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pilocarpine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cantharidin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ethinyl-estradiol-5991 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/progesterone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/finerenone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/levodopa yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/gemcitabine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lamivudine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/emtricitabine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/methylene-blue yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/calcium-oxybate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cytarabine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/trifluridine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sildenafil-citrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/amoxicillin-trihydrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ciprofloxacin-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sertraline-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/rifabutin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dihydroergotamine-mesylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/perflutren yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tapinarof yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/cannabidiol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/buprenorphine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/rilpivirine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/iopamidol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/artesunate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/glecaprevir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/darolutamide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/erdafitinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ledipasvir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/solriamfetol-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/velpatasvir yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/brigatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/nifurtimox yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fexinidazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/drospirenone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/milnacipran-hcl yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dexmedetomidine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/treprostinil-sodium-6918140 yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ganaxolone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ceftobiprole-medocaril yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/voclosporin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sugammadex-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/triheptanoin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/teduglutide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/n-acetyl-l-leucine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/phentermine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/osilodrostat-phosphate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/acalabrutinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/iloperidone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/viloxazine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/trientine-tetrahydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/selinexor yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tenofovir-alafenamide-fumarate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/plazomicin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ripretinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/imetelstat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/voxelotor yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/futibatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ivosidenib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lorlatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tazemetostat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/omaveloxolone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/secnidazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/terlipressin-acetate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/atogepant yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/asciminib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/isavuconazonium-sulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/taletrectinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/arimoclomol-citrate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/umbralisib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pexidartinib-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/rilzabrutinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/leuprolide-mesylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fosfomycin-sodium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dordaviprone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/irinotecan-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/zoliflodacin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lotilaner yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/oteseconazole yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tenapanor-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/abrocitinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/niraparib-tosylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/osimertinib-mesylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/vimseltinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ferric-carboxymaltose yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/zuranolone yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/sofpironium-bromide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/lefamulin-acetate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/patiromer-sorbitex-calcium yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pemigatinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/leniolisib-phosphate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/iptacopan-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/phentolamine-mesylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/daprodustat yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/seladelpar-lysine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/daridorexant-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/etripamil yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/difelikefalin-acetate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/motixafortide yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/valbenazine-tosylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/apomorphine-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/azacitidine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/chlorhexidine-gluconate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/iron-sucrose yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/nintedanib-esylate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/mirdametinib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/maralixibat-chloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/moxidectin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tapentadol yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/abacavir-sulfate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/fluticasone-furoate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/elafibranor yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/prucalopride-succinate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/treosulfan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/dapagliflozin yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tipiracil-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tivozanib yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tradipitant yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/avatrombopag-maleate yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/melphalan-hydrochloride yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/ensifentrine yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/olive yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/patisiran yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/inclisiran yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/pegcetacoplan yearly 0.7 https://www.pharmacompass.com/fda-orange-book-exclusivity/tirzepatide yearly 0.7